FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667145> ?p ?o ?g. }

• W4385667145 endingPage "e3891642" @default.
• W4385667145 startingPage "e3891642" @default.
• W4385667145 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas, with a poor prognosis and a shortened survival for relapsed or refractory (R/R) disease. In the 5th edition of the World Health Organization (WHO) classification of NK and T-cell lymphomas, there are 39 entries, of which the 3 most common subtypes in the US are PTCL-NOS (not otherwise specified), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL). With the exception of brentuximab vedotin (BV) in CD30-positive disease, these agents were generally approved based on overall response rates (ORR) of less than 30%. The PRIMO Trial (NCT03372057; sponsored by Secura Bio, Inc.) evaluates duvelisib (DUV), an oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ and PI3K-γ isoforms, in PTCL. Anti-tumor activity of single agents may not be uniform across the different subtypes of PTCL. Here we present data on the 3 specific subtypes by histology of some of the patients included in the PRIMO trial, which is fully enrolled as of January 2022. Aims: The primary objective of the PRIMO Trial Expansion Phase was to determine the efficacy of duvelisib at an optimal dose in patients with R/R PTCL; secondary objectives included additional outcome measures, tolerability and safety, and pharmacokinetics. Exploratory endpoints included pharmacodynamics and biomarkers. Methods: Eligibility criteria included adult individuals with pathologically confirmed PTCL (defined per the 2016 revision of the WHO classification of lymphoid neoplasms), after ≥2 cycles of at least 1 prior standard regimen. A criterion for a CD4 lymphocyte count of ≥50/mm3 was added for the Expansion Phase. Based on dose optimization results, the protocol dose in the Expansion Phase was DUV 75 mg BID for 2 cycles, to maximize disease control, followed by 25 mg BID, to mitigate late toxicities, until progressive disease or unacceptable toxicity. Pneumocystis jirovecii prophylaxis was required; herpes simplex and varicella zoster virus prophylaxis were also indicated as needed. The primary endpoint was ORR by Independent Review Committee (IRC) assessment using Lugano 2014 criteria; efficacy is or will be assessed in all patients that received ≥1 dose of DUV. Results: The PRIMO study included 101 patients from the Expansion Phase (data cutoff Oct 1, 2021), with a median follow-up of 8.7 months (mo) from time of first response. In the overall PRIMO study (N=101), patients had a median age of 67 years (range, 21-92), with a median of 3 prior lines of therapy (range 1-9). The overall population (N=101) had an ORR (by IRC) of 49%, a complete response rate of 34%, and a median PFS of 3.6 mo. Patients with the 3 most common baseline histology subtypes from the PRIMO study are included in the current analysis (n=97); these are PTCL (n=52), AITL (n=30), and ALCL (n=15). The median progression-free survival (PFS) stratified by baseline histology was 3.5 mo for PTCL-NOS, 9.1 mo for AITL, and 1.5 mo for ALCL. Additional outcomes stratified by baseline histology are shown in Table 1. The types of adverse events seen were consistent with those observed previously in the PRIMO trial with no additional unexpected treatment-related toxicities. Summary/Conclusion: The ORR (by IRC) of duvelisib was higher in patients with PTCL-NOS (48%) and AITL (67%), compared with ALCL (13%). This corresponded to a longer median PFS of 3.5 mo in PTCL-NOS and 9.1 mo in AITL compared with 1.5 mo in ALCL. Although not powered for subset analyses, this analysis suggests activity of duvelisib may not be uniform across different types of lymphomas.Keywords: Non-Hodgkin’s lymphoma, PI3 kinase, Peripheral T-cell lymphoma" @default.
• W4385667145 created "2023-08-09" @default.
• W4385667145 creator A5003367392 @default.
• W4385667145 creator A5010723896 @default.
• W4385667145 creator A5013307217 @default.
• W4385667145 creator A5014614303 @default.
• W4385667145 creator A5048980215 @default.
• W4385667145 creator A5060010434 @default.
• W4385667145 creator A5063072439 @default.
• W4385667145 creator A5064738578 @default.
• W4385667145 creator A5069406522 @default.
• W4385667145 creator A5074536375 @default.
• W4385667145 creator A5078705613 @default.
• W4385667145 creator A5083104525 @default.
• W4385667145 creator A5091882595 @default.
• W4385667145 date "2023-08-01" @default.
• W4385667145 modified "2023-10-17" @default.
• W4385667145 title "P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY" @default.
• W4385667145 doi "https://doi.org/10.1097/01.hs9.0000971392.38916.42" @default.
• W4385667145 hasPublicationYear "2023" @default.
• W4385667145 type Work @default.
• W4385667145 citedByCount "0" @default.
• W4385667145 crossrefType "journal-article" @default.
• W4385667145 hasAuthorship W4385667145A5003367392 @default.
• W4385667145 hasAuthorship W4385667145A5010723896 @default.
• W4385667145 hasAuthorship W4385667145A5013307217 @default.
• W4385667145 hasAuthorship W4385667145A5014614303 @default.
• W4385667145 hasAuthorship W4385667145A5048980215 @default.
• W4385667145 hasAuthorship W4385667145A5060010434 @default.
• W4385667145 hasAuthorship W4385667145A5063072439 @default.
• W4385667145 hasAuthorship W4385667145A5064738578 @default.
• W4385667145 hasAuthorship W4385667145A5069406522 @default.
• W4385667145 hasAuthorship W4385667145A5074536375 @default.
• W4385667145 hasAuthorship W4385667145A5078705613 @default.
• W4385667145 hasAuthorship W4385667145A5083104525 @default.
• W4385667145 hasAuthorship W4385667145A5091882595 @default.
• W4385667145 hasBestOaLocation W43856671451 @default.
• W4385667145 hasConcept C126322002 @default.
• W4385667145 hasConcept C143998085 @default.
• W4385667145 hasConcept C197934379 @default.
• W4385667145 hasConcept C203014093 @default.
• W4385667145 hasConcept C2776090121 @default.
• W4385667145 hasConcept C2777589544 @default.
• W4385667145 hasConcept C2777872185 @default.
• W4385667145 hasConcept C2777891184 @default.
• W4385667145 hasConcept C2778191690 @default.
• W4385667145 hasConcept C2778375690 @default.
• W4385667145 hasConcept C2779338263 @default.
• W4385667145 hasConcept C31760486 @default.
• W4385667145 hasConcept C535046627 @default.
• W4385667145 hasConcept C70905583 @default.
• W4385667145 hasConcept C71924100 @default.
• W4385667145 hasConcept C8891405 @default.
• W4385667145 hasConceptScore W4385667145C126322002 @default.
• W4385667145 hasConceptScore W4385667145C143998085 @default.
• W4385667145 hasConceptScore W4385667145C197934379 @default.
• W4385667145 hasConceptScore W4385667145C203014093 @default.
• W4385667145 hasConceptScore W4385667145C2776090121 @default.
• W4385667145 hasConceptScore W4385667145C2777589544 @default.
• W4385667145 hasConceptScore W4385667145C2777872185 @default.
• W4385667145 hasConceptScore W4385667145C2777891184 @default.
• W4385667145 hasConceptScore W4385667145C2778191690 @default.
• W4385667145 hasConceptScore W4385667145C2778375690 @default.
• W4385667145 hasConceptScore W4385667145C2779338263 @default.
• W4385667145 hasConceptScore W4385667145C31760486 @default.
• W4385667145 hasConceptScore W4385667145C535046627 @default.
• W4385667145 hasConceptScore W4385667145C70905583 @default.
• W4385667145 hasConceptScore W4385667145C71924100 @default.
• W4385667145 hasConceptScore W4385667145C8891405 @default.
• W4385667145 hasIssue "S3" @default.
• W4385667145 hasLocation W43856671451 @default.
• W4385667145 hasLocation W43856671452 @default.
• W4385667145 hasOpenAccess W4385667145 @default.
• W4385667145 hasPrimaryLocation W43856671451 @default.
• W4385667145 hasRelatedWork W170895960 @default.
• W4385667145 hasRelatedWork W1968380476 @default.
• W4385667145 hasRelatedWork W2017608397 @default.
• W4385667145 hasRelatedWork W2205257049 @default.
• W4385667145 hasRelatedWork W2412306442 @default.
• W4385667145 hasRelatedWork W2885553082 @default.
• W4385667145 hasRelatedWork W2983741958 @default.
• W4385667145 hasRelatedWork W3131095990 @default.
• W4385667145 hasRelatedWork W3134180800 @default.
• W4385667145 hasRelatedWork W4240810606 @default.
• W4385667145 hasVolume "7" @default.
• W4385667145 isParatext "false" @default.
• W4385667145 isRetracted "false" @default.
• W4385667145 workType "article" @default.